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Abstract
Retrospective studies have demonstrated that nearly 50% of patients with ovarian cancer with normal cancer
antigen 125 (CA125) levels have persistent disease; however, prospectively distinguishing between patients is
currently impossible. Here, we demonstrate that for one patient, with the first reported fibroblast growth factor
receptor 2 (FGFR2) fusion transcript in ovarian cancer, circulating tumor DNA (ctDNA) is a more sensitive and spe-
cific biomarker than CA125, and it can also inform on a candidate therapeutic. For a 4-year period, during which the
patient underwent primary debulking surgery and chemotherapy, tumor recurrences, and multiple chemotherapeutic
regimens, blood samples were longitudinally collected and stored. Whereas postsurgical CA125 levels were elevated
only three times for 28 measurements, the FGFR2 fusion ctDNA biomarker was readily detectable by quantitative
real-time reverse transcription–polymerase chain reaction (PCR) in all of these same blood samples and in the
tumor recurrences. Given the persistence of the FGFR2 fusion, we treated tumor cells derived from this patient
and others with the FGFR2 inhibitor BGJ398. Only tumor cells derived from this patient were sensitive to FGFR2
inhibitor treatment. Using the same methodologic approach, we demonstrate in a second patient with a different
fusion that PCR and agarose gel electrophoresis can also be used to identify tumor-specific DNA in the circulation.
Taken together, we demonstrate that a relatively inexpensive, PCR-based ctDNA surveillance assay can outperform
CA125 in identifying occult disease.
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Highlights
Although clinical utility and cost-effectiveness of the differing circulat-
ing tumor DNA (ctDNA)–detecting strategies, and even the overall
approach of using ctDNA as a biomarker, have yet to be determined,
the daily reality faced by oncologists and patients is that more sensitive
and specific biomarkers are needed. In many instances, currently Food
and Drug Administration (FDA)-approved biomarkers may be pro-
viding an incomplete, hence, misleading, assessment of disease status.
To our knowledge, this use of a personalized biomarker represents
the first example in ovarian cancer demonstrating the presence of con-
tinuous occult disease in the face of negative clinical, radiologic, and
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biochemical examination. Moreover, the recent identification of fibro-
blast growth factor receptor (FGFR) fusions in other solid cancers
suggests a broader application of this strategy beyond ovarian cancer.
Introduction
The measurement of ctDNA, the so-called liquid biopsy, suggests great
potential for radically transforming our current diagnostic and prog-
nostic abilities in human cancers [1]. The origins of the “liquid biopsy”
have evolved from the first description of circulating freeDNA (cfDNA)
in human serum [2] to the original demonstration of increased cfDNA
in cancer and other diseases [3]. More recently, a number of studies
have demonstrated the ability to assess tumor dynamics and disease
burden in patients undergoing treatment by following levels of ctDNA
[4], as a quantitative marker for metastatic disease monitoring and
treatment response [5] and even to monitor the evolution of tumor
mutations and acquired resistance to treatment [6,7]. In some instances,
structural variants present only in a patient’s tumor and detected by
massively parallel sequencing have provided an opportunity to generate
highly specific, personalized tumor markers enabling monitoring of
patients throughout their disease course [8,9]. We report the case of
a 59-year-old female who was originally diagnosed and treated for
stage III ovarian cancer and highlight the use of genomic technologies
to deliver a tool for more accurate disease surveillance and, concur-
rently, identification of a candidate therapy.
Materials and Methods
Patients and Patient-Derived Samples
Blood and tumor samples were collected from patients at the Icahn
School of Medicine at Mount Sinai (New York, NY) after obtaining
appropriate informed consent as a part of our Institutional Review
Board (IRB)-approved personalized ovarian cancer genomics program.
For serum and plasma separation, blood samples were collected in BD
Vacutainer SST Plus Blood Collection Tubes (BD Biosciences, San
Jose, CA) and processed between 4 to 6 hours after collection. Blood
samples were centrifuged at 2600 and 1200 rpm for 10 minutes at
4°C, for separation of serum and plasma, respectively. All samples
were aliquoted and stored at −130°C until use.
Tumor RNA Extraction and RNA Sequencing (RNA-Seq)
RNA was extracted from frozen tumor tissue using QIAzol accord-
ing to manufacturer’s instructions (Qiagen, Valencia, CA). Briefly,
tissue was homogenized in QIAzol on ice. Chloroform was then
added, mixed, and centrifuged to allow for separation and removal
of the aqueous layer. RNA was precipitated in isopropanol overnight
at −20°C. The suspension was centrifuged to pellet RNA, washed
with 75% ethanol, and resuspended in RNAase-free water. RNA integ-
rity numbers were analyzed (Agilent Bioanalyzer; Agilent Technologies,
Santa Clara, CA), and only RNA samples with an RNA integrity
number of >8.0 were submitted for next-generation sequencing.
Ovarian cancer transcriptomes were prepared for paired-end
sequencing (100 bp) on the Illumina GAII platform and using the
Roche NimbleGen capture kit (version 2.0; Madison, WI), always
using the manufacturers’ protocols but with a second size selection
step to reduce ligation artifacts. Reads were aligned using Eland32
[provided with the Illumina sequencing platform (SanDiego, CA)]. Ex-
pression levels were quantified by running ERANGE version 3.0.2
(http://woldlab.caltech.edu/rnaseq). For each gene, ERANGE re-
ported the number of mapped reads per kilobase of exon per million
mapped reads.
Identification of Gene Fusion Transcripts from RNA-Seq
We identified chimeric transcripts through examination of the
spliced alignment of ∼30 million raw cDNA high-quality paired-end
reads to a reference human genome (GRCh37/hg19), using two
independent algorithm approaches. FusionHunter and TopHat-
Fusion-Post with deFuse were used to parse through potential fusion
candidates with a battery of stringent selection filters [10−12]. Fusion
transcripts were confirmed by direct sequencing of tumor DNA and
RNA and their tumor-specific expression by sequencing of paired
peripheral blood mononuclear cell (PBMC) genomic DNA.
Isolation of Tissue Genomic and Circulating DNA
Genomic DNA was extracted from PBMCs and tumor samples using
the DNeasy Blood and Tissue Kit according to the manufacturer’s pro-
tocol (Qiagen). Circulating DNA was extracted from 200-μl aliquots
of patient serum or plasma using the QIAamp MinElute Virus Spin
Kit according to the manufacturer’s recommended protocol (Qiagen).
ctDNA was eluted with 100 μl of DNase- and RNase-free water.
Detection of FGFR2-FAM76A Fusion DNA in ctDNA
To detect the tumor-specific FGFR2-family with sequence simi-
larity 76, member A (FAM76A) fusion in serum and/or plasma,
we performed quantitative polymerase chain reaction (qtPCR) using
iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) on
an ABI PRISM 7900HT Sequence Detection System (Applied Bio-
systems, Foster City, CA). The primers used were as follows: fusion,
forward—2 5′-GGATAAAGGAAGAGATTGCAC-3′ and fusion,
reverse—2 5′ TGTGGGAGTTAAGTAAGAACT-3′. For each reac-
tion, 5 μl of extracted ctDNA was used. Quantification was performed
using a standard curve designed to assign quantities to each sample.
The standard curve was prepared from a series of 10-fold dilutions
covering a range of 101 to 106 copies of a purified FGFR2-FAM76A
fusion gene fragment. DNA was used for the standard curve prepara-
tion, and PCR was performed on tumor genomic DNA using the
following specific primers: fusion, forward—3 5′-TCTTATGCG-
TCTGACTGTGG-3′ and fusion, reverse—2 5′-TACTGGCATCA-
CTTCCCTA-3′. The 186-bp PCR product was gel purified and
quantified. PCR conditions used for amplification of this fragment
were 94°C (5 minutes) for 1 cycle, 94°C (15 seconds), 55°C (15 sec-
onds), and 72°C (20 seconds) for 35 cycles each, and a final extension
of 72°C (10 minutes). Fusion copy number is expressed as the number
of copies present in 5 μl of ctDNA.
For these studies, we also used two positive internal controls. First,
and in addition to assaying for the fusion, we also tested for the presence
of a DNA sequence [glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; actin)] present in both germ line and tumor DNA. Theo-
retically, if the control sequence was not detected, then the assay was
repeated. This never occurred. Second, we also “spiked” the patient
blood samples with a set concentration of plasmid DNA (pBluescript;
Agilent Technologies) before ctDNA isolation. This allowed us to
define reproducibility of the assay between sample runs and the
efficiency of DNA extraction. Using quantitative real-time reverse
transcription–PCR (qtRT-PCR), extractions resulted in a calculated
recovery efficiency of between 30% to 75% of the spiked plasmid
sample. All experiments were performed in triplicate and each done
at least twice.
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Generation of FGFR2-FAM76A Expression Constructs
To generate the fusion FGFR2-FAM76A–expressing construct,
we amplified the full-length cDNA from patient tumor RNA using
RT-PCR. Amplification was performed using the following set of
primers: forward primer—5′-ATGGTCAGCTGGGGTCGTTTC-3′
(located at the translational start site of FGFR2 exon 1) and reverse
primer—5′-TCATGGAGAGGTTATAGCTCCTG-3′ (present in
the last exon of FAM76A). The native FAM76A stop codon was ex-
cluded to allow the generated product to express the vector’s V5 epitope.
The PCR cycling conditions were 94°C (5 minutes) for 1 cycle, 94°C
(30 seconds), 55°C (1 minute), and 72°C (2 minutes) for 35 cycles
each, and a final extension of 72°C (10minutes). The amplified products
were electrophoretically separated on an agarose gel, excised, and cloned
into the pcDNA3.1/V5-His TOPO TA expression vector (Invitrogen,
Carlsbad, CA). All constructs were confirmed by Sanger sequencing in
both orientations before their use.
RNA Isolation and qtRT-PCR
Cell line RNA was extracted using RNeasy Mini Kits, including
treatment with DNase according to the manufacturer’s protocol
(Qiagen). For RT-PCR, we used a total of 1 μg of RNA per reaction
using iSCRIPT cDNA Synthesis following the manufacturer’s protocol
(Bio-Rad Laboratories). FGFR2-FAM76A RNA levels were measured
using qtRT-PCR as described below using the following genomic
specific primers: fusion, forward—one 5′-CAGAGACCAACGTTCA-
AGCAGT-3′ and fusion, reverse—5′-GGTTTTACTCTCCTGCT-
GGTACT-3′. All values were normalized either with GAPDH or
hypoxanthine phosphoribosyltransferase 1 (HPRT) levels, and then
the normalized value was used to calculate fold change compared with
control. All experiments were done in triplicate and independently
validated at least three times.
Western Blot Assay
Cell extracts were harvested in radioimmunoprecipitation assay
buffer [Santa Cruz Biotechnology (Dallas, TX) standard protocol].
Equal amounts of protein (50 μg) as determined by the Bio-Rad DC
Protein quantification assay were loaded and separated by polyacryl-
amide gel electrophoresis and transferred to nitrocellulose membranes.
We performed immunoblot analysis by using goat polyclonal antibody
to β-actin (SC-1615) and monoclonal antibody to the V5 tag (Santa
Cruz Biotechnology) present in the FGFR2-FAM76A constructs.
Cell Culture and Transfections
CP70 cell line [obtained from ATCC (Manassas, VA)] and patient-
derived tumor cell lines were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% FBS, 100 U/ml penicillin,
and 100 mg/ml streptomycin and grown at 37°C in 5% CO2. For
the generation of CP70 stable cell lines expressing FGFR2-FAM76A
and Lac-Z, cells were transfected 24 hours after plating with 10 μg
of each construct using Lipofectamine 2000 according to the manu-
facturer’s suggestions (Invitrogen). Twenty-four hours following trans-
fection, cells were selected for in the presence of 2 mg/ml G418 (Life
Technologies, Grand Island, NY). For these experiments, only early-
passage (<passage 5) patient-derived tumor cell lines were used.
Cell Proliferation
Cell proliferation was determined at 24 and 48 hours by [3H]
thymidine incorporation (1 mCi/ml; PerkinElmer, Waltham, MA).
CP70 stable cell lines were plated at a density of 5000 cells per
cm2 in 12-well dishes. At 24- and 48-hour time points, 1 μCi [3H]
thymidine was added and incubated for 3 hours, then washed three
times with cold phosphate-buffered saline, and fixed in methanol for
30 minutes at 4°C. Methanol removal and cell drying were performed,
and cells were solubilized in 0.25% sodium hydroxide/0.25% sodium
dodecyl sulfate and neutralized with hydrochloric acid (1 N). Disinte-
grations per minute were estimated by liquid scintillation counting.
The proliferation index was calculated by dividing the counts obtained
at 48 hours by the counts obtained at 24 hours. Each experiment was
performed in triplicate and repeated three times.
Colony Formation Assay in Soft Agar
The ability of different transfectants to induce changes in prolifera-
tion in an anchorage-independent manner was quantified by standard
soft agar assay. Approximately 5 × 105 cells were resuspended in 2.5 ml
of Dulbecco’s modified Eagle’s medium supplemented with 20% FBS;
then, 2.5 ml of 0.8% (wt/vol) SeaPlaque Agarose (Lonza, Rockland,
ME) was added and carefully resuspended, and 1.5 ml of this mix was
overlaid on top of three six-well plates containing 1% (wt/vol) agar.
After 2 weeks of incubation at 37°C, colonies were visualized and
counted after staining with 1 mg/ml p-iodonitotetrazonium violet.
All experiments were performed in triplicate and repeated three times.
BGJ398 Treatment and 3-[4,5-Dimethylthiazol-2-yl]-2,
5-Diphenyltetrazolium Bromide (MTT) Assay
CP70 stables and patient-derived tumor cell lines were plated onto
96-well plates and, 24 hours later, incubated for 48 hours in the pres-
ence and absence of 4, 8, and 16 mM BGJ398 (No. S2183; Selleck,
Houston, TX). CP70 stable cell lines were plated at a density of 10 ×
103 cells per cm2 and patient-derived tumor cells at a density of 6 ×
103 cell per cm2. Cell viability was measured using a standard MTT
(thiazolyl blue) assay. Absorbance at 570 nm was measured using
a microplate reader (Turner BioSystems Inc, Sunnyvale, CA). All
experiments were performed in triplicate and repeated three times.
Nested PCR Detection of RANGAP1-PVALB Fusion
Nested PCR was performed for detection of the Ran GTPase
Activating Protein 1 (RANGAP1)-Parvalbumin (PVALB) fusion in
ctDNA extracted from patient serum and plasma. Two sequential
rounds of PCR were performed. Primers for the first PCR round
were given as follows: RANGAP1, forward 1—5′ GCTGGGA-
TGATTTTTCATCCTTG and PVALB, reverse 1—5′ AGTCAGG-
AAATGGGCGTGAATTA. In the first round, 1 μl of extracted
ctDNA was used for each reaction. Primers for the second PCR round
were given as follows: RANGAP1, forward 2—5′ TCATTCACTC-
ATTCATTCCCTCTC and PVALB, reverse 2—5′ TTACCTCTTC-
CATTGCCGGG. For each reaction, 1 μl of PCR product from the
first PCR round was used. PCR conditions used for both PCR rounds
were 94°C (5 minutes) for 1 cycle, 94°C (15 seconds), 55°C (15 sec-
onds), and 72°C (20 seconds) for 30 cycles each, and a final extension
of 72°C (10 minutes).
Results
At the time of the patient’s original surgery 4 years ago, the serum
level of the tumor marker cancer antigen 125 (CA125) was mildly
elevated at 40 U/ml. At the conclusion of surgery, cytoreduction
was considered optimal with no evidence of residual disease. The
pathologic diagnosis was stage IIIC moderately differentiated papil-
lary serous carcinoma. As part of our IRB-approved personalized
Neoplasia Vol. 16, No. 1, 2014 Personalized ctDNA Biomarkers in Ovarian Cancer Martignetti et al. 99
cancer genomics program, fresh frozen tumor and blood samples were
collected for deposit in a specialized tumor bank.
CA125 is the only biomarker recommended for both monitoring
of therapy and detection of recurrence in ovarian cancer. For this
past 4 years, and following the original surgery, CA125 levels only
exceeded upper limits of normal in 3 of 28 tests. Despite this, the
patient has had a series of biopsy-proven tumor recurrences even
in the face of normal CA125 levels. These recurrences were managed
with interval debulking and the empirical use of second- and third-
line chemotherapy treatments (Figure 1, top panel). Given this his-
tory, we wondered whether a genomics-based approach could pro-
vide a more sensitive surveillance strategy than reliance on CA125
levels. We therefore used high-throughput RNA sequencing of the
patient’s primary and initial recurrent tumor, coupled with bioinfor-
matic analysis, to search for tumor-specific gene fusions. The chimeric
junction sequences were used for developing tumor-specific, qtRT-
PCR primers.
In this patient, both fusion detection algorithms that we used in
our sequence analysis pipeline, FusionHunter and TopHat-Fusion-
Post with deFuse {[10–12], respectively}, supported identification
of an in-frame, interchromosomal FGFR2(chr10)-FAM76A(chr1)
translocation with excellent statistical confidence in both the primary
and recurrent tumor samples (Figure W1). These RNA-Seq findings
were verified by qtPCR and Sanger sequencing (Figure W2). We
mapped the genomic breakpoint using long-range PCR and identi-
fied the intervening introns between these two genes (Figure W3). Of
particular interest, and suggesting that this may represent a relatively
frequent event in human cancers, the ovarian FGFR2 genomic break-
point is identical to that present in several solid human tumor types that
were recently reported [13]. The breakpoints, using the University of
California Santa Cruz (UCSC) Genome Browser hg19 coordinates, are
FGFR2(chr10), position 123243211 and FAM76A(chr1), 28053982.
As would be expected for a tumor-specific event, the FGFR2-FAM76A
ovarian fusion was present only in tumor-derived DNA but not germ
line DNA. The fusion preserves almost the entire length of the FGFR2
protein, including the terminal tyrosine kinase domains, and main-
tains the FAM76A coding sequence in-frame beginning in exon 2.
qtRT-PCR primers were designed to amplify the sequence of the
genomic breakpoint. ctDNA was extracted from 200 μl of either
plasma or serum from each of a total of 28 samples collected and
stored frozen since the patient’s original surgery 4 years ago. Signifi-
cantly, the tumor-specific fusion is consistently detectable in the circu-
lation throughout the course of the patient’s postsurgical and multiple
chemotherapy treatments, indicating the continued presence of occult
tumor cells (Figure 1, bottom panel). In direct contrast to the presence
of pathologic ctDNA, CA125 levels were elevated only three times
Figure 1. Detection of fusion sequences in ctDNA. (A) The surgical (highlighted in yellow) and chemotherapy (purple) events associated
with the patient’s history. Serum CA125 levels (red), determined at the time blood samples were originally drawn, and FGFR2-FAM76A
copy number present in ctDNA in plasma are plotted. ctDNA copy number was divided by 33.3 to allow CA125 levels and ctDNA values
to be plotted on the same graph. Fusion levels were determined using qtRT-PCR. The red line represents the upper limit of normal for
CA125 (20 U/ml; Quest Diagnostics, Madison, NJ).
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Figure 2. FGFR2-FAM76A fusion increases cell proliferation. (A) Western blot analysis demonstrates stable ectopic expression of FGFR2-
FAM76A fusion in the generated CP70 cell line. β-Actin, loading control. (B and C) Expression of FGFR2-FAM76A increases cellular
proliferation and anchorage-independent growth, respectively, when the fusion is stably expressed in the cisplatin-resistant cell line
CP70 and compared to the forced expression of the control protein Lac-Z. ***P < .001. (D) CP70 cells expressing the FGFR2-FAM76A
fusion are more sensitive than control cells to cell death when treated with the pan-FGFR inhibitor BGJ398.
Figure 3. Targeted treatment of patient-derived cell lines. Early-passage ascites cells from three different patients, all with chemonaive,
primary stage III ovarian cancer, were grown and treated with the pan-FGFR inhibitor BGJ398. Only tumor cells expressing the FGFR2-
FAM76A fusion are sensitive to treatment. ns, not significant. ***P < .001.
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following the initial surgery. Taken together, these findings suggest the
persistence of residual disease during this 4-year period.
The constancy of the FGFR2-FAM76A fusion in each of the sub-
sequently isolated biopsy samples (surgical dates are highlighted in
yellow in Figure 1) further suggested a possible biologic pressure
to maintain this transcript throughout tumor evolution and spread.
Therefore, to begin assessing its potential functional role, we first
constructed CP70 cisplatin-resistant ovarian cancer cell lines stably
expressing the fusion protein to examine both the effect of FGFR2
fusion expression and inhibition on tumor cell behavior. Expression
of the FGFR2 fusion (Figure 2A) resulted in increasing proliferation
of the ovarian cancer cells by more than 50% (Figure 2B). Similarly,
expression of the fusion increased the anchorage-independent growth
of these cells in soft agar by nearly 50% (Figure 2C ).
Given these findings demonstrating a functional effect of the
FGFR2-FAM76A fusion, we wanted to next determine the effect of
targeted inhibition of this fusion protein. We therefore assessed the
antiproliferative effect of the pan-FGFR inhibitor BGJ398, currently
in phase I clinical trials for patients with advanced solid malignancies
and FGFR2 amplification. As shown (Figure 2D), this inhibitor had
a magnified effect on decreasing cell proliferation in the tumor cells
ectopically expressing the FGFR2 fusion. To gain more direct evidence
of the effect of the FGFR2-FAM76A fusion on tumor cell growth and
its possible therapeutic candidacy, we next analyzed the effect of the
inhibitor on patient-derived tumor cell lines. Specifically, the effect
of FGFR inhibition was compared between patient-derived ascites cell
lines from this patient and two other patients (ISM1 and ISM2) who
had also presented with stage IIIC primary ovarian cancer (Figure 3).
The FGFR2-FAM76A fusion was present, in both DNA and RNA,
exclusively in the tumor cells from our original patient but not in the
other two patient-derived cell lines ISM1 and ISM2. Treatment with
BGJ398, depending on dose, significantly reduced cell viability by
more than 40% in the FGFR fusion–expressing cell line. In the other
two cell lines, treatment with the FGFR inhibitor had no significant
effect on cell viability.
We tested this overall approach in a second patient in whom we had
detected a different fusion. This patient’s pathologic diagnosis fol-
lowing primary surgery in 2011 was also stage IIIC moderately differ-
entiated papillary serous carcinoma with optimal surgical debulking.
RNA-Seq analysis identified an intrachromosomal deletion (chr22)
leading to the generation of the fusion transcript RANGAP1-PVALB
(Figure W4). ctDNA containing this specific fusion was retrospectively
identified in blood samples stored and frozen for a 2-year period using
PCR and agarose gel electrophoresis (Figure 4). Direct Sanger se-
quencing of the resultant amplicons confirmed the fusion. All seven
of the serum samples collected, and which spanned the time frame
from original surgery to now, demonstrated the presence of the fusion
product in ctDNA. This finding was consistent with the recent recur-
rence of clinically demonstrable disease and the fact that the fusion was
present in the recurrent tumor’s genomic DNA.
Discussion
In general, levels of cfDNA—not distinguishing between tumor or
normal cell origin—have previously been shown to be elevated in
high-grade, advanced stage serous ovarian carcinomas, suggesting the
possibility of noninvasive screening and surveillance [14]. Given the
large number of deletions, insertions, and chromosomal translocations
inherent in ovarian cancer [15], this cancer type may be ideally suited
for generating tumor-specific sequences on the basis of the detection
of structural variants that can be serially detected with theoretically
exquisitely high specificity from blood samples. In general, levels
of cfDNA has previously been shown to be elevated in high-grade,
advanced stage serous ovarian carcinomas. Of particular interest, with
respect to the robustness of our approach, is that minimal amounts of
serum/plasma (less than 0.5 ml) were used for DNA extraction for the
ctDNA assays. Moreover, many of these samples were stored frozen for
several years. The approach we have outlined is also highly flexible
with regard to methodology used for the surveillance assays. For exam-
ple, and as demonstrated in the second patient, standard, nonqualita-
tive PCR could also be used to provide an even more inexpensive and
rapid assay when compared to qtRT-PCR. Taken together, we believe
that the specificity and flexibility of this overall approach provides yet
another step toward the goal of providing precision cancer diagnostics
and eventually improving quality of life and survival.
In our patient with FGFR2-FAM76A, RNA-Seq analysis at the time
of her primary surgery identified a highly specific ctDNA biomarker,
and in particular, the analysis identified a candidate growth driver and
drug target. What was initially unexpected, but biologically consistent
given the patient’s tumor recurrences, was that every ctDNA assay
was positive, consistent with the existence of residual disease. This
was in direct contrast to an overwhelming number of normal inter-
vening CA125 levels and interspersed normal radiologic studies. As
has been previously suggested [8], if these ctDNA assays could be per-
formed in real time following a patient’s original surgery, the detection
of residual disease would trigger more aggressive/different treatment
options at an earlier time point, cessation of ineffective, systemically
Figure 4. Detection of ctDNA fusion by PCR and gel electrophoresis. Fusion sequences can also be detected in serum/plasma using
standard PCR and gel electrophoresis. The RANGAP-PVALB fusion was detected using nested PCR (a total of 60 amplification cycles) in
all serum/plasma samples from patient No. 2. As expected, the fusion was not detected in the patient’s germ line DNA isolated from
PBMC. The patient’s time line from which blood samples were originally drawn and stored away frozen is shown above the gel.
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toxic treatments, and/or directed participation in a clinical trial. For
this patient, the complete range of precision medicine goals are in
evidence starting with the development of PCR-based, rapid (<24-hour
turnaround) and inexpensive disease surveillance assays coupled with
the identification of a candidate-tailored therapeutic strategy. In a set-
ting where up to 50% of patients with ovarian cancer with normal
CA125 levels following chemotherapy are known to have persistent
disease [16], the value and limitations of ctDNA-based biomarkers
in this disease need to be further explored if we are to avoid losing
opportunities for improving management and treatment.
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Figure W1. Genomic breakpoint sequence and overview of the FGFR2-FAM76A fusion. Sequence positions are based on alignment with
hg19 from the UCSC Genome Browser.
Figure W2. FGFR2-FAM76A fusion RT-PCR validation. The fusion was validated using two different primer pairs, with predicted products
of∼280 bp (primer No. 1) and∼500 bp (primer No. 2), spanning the chimeric sequence. RNA was isolated from noncancerous peritoneum
adjacent to the tumor (N), primary tumor (P), and an omental metastasis (M). The fusion was present only in cancerous tissue. β-Actin was
amplified from all samples. All amplicons were isolated and confirmed by Sanger sequencing.
Figure W3.Mapping of the FGFR2-FAM76A genomic breakpoint. Long-range PCR was used to isolate the fusion product from genomic
DNA isolated from the patient’s primary tumor. The fusion product is present only in tumor (T) but not germ line (G) DNA.
Figure W4. Genomic breakpoint sequence and overview of the RANGAP1-PVALB fusion. Sequence positions are based on alignment
with hg19 from the UCSC Genome Browser.
